156 related articles for article (PubMed ID: 29750539)
1. Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218.
Timon G; Ciardo D; Bazani A; Marvaso G; Riva G; Volpe S; Rojas DP; Renne G; Petralia G; Zerini D; Fodor C; Dicuonzo S; Maestri D; Pansini F; Cambria R; Cattani F; Golino F; Scroffi V; De Lorenzo D; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Br J Radiol; 2018 Sep; 91(1089):20160725. PubMed ID: 29750539
[TBL] [Abstract][Full Text] [Related]
2. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
[TBL] [Abstract][Full Text] [Related]
3. Phase II prospective trial "Give Me Five" short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218).
Marvaso G; Gugliandolo SG; Bellerba F; Gandini S; Corrao G; Volpe S; Rojas DP; Riva G; Zerini D; Pepa M; Fodor CI; La Rocca E; Pricolo P; Alessi S; Petralia G; Mistretta FA; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2020 Jul; 37(8):74. PubMed ID: 32725443
[TBL] [Abstract][Full Text] [Related]
4. Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE".
Marvaso G; Corrao G; Repetti I; Lorubbio C; Bellerba F; Zaffaroni M; Vincini MG; Zerini D; Alessi S; Luzzago S; Mistretta FA; Fodor C; Cambria R; Cattani F; Ceci F; Musi G; De Cobelli O; Zilli T; Gandini S; Orecchia R; Petralia G; Jereczek-Fossa BA
World J Urol; 2024 Mar; 42(1):169. PubMed ID: 38492078
[TBL] [Abstract][Full Text] [Related]
5. Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion.
Timon G; Ciardo D; Bazani A; Garioni M; Maestri D; De Lorenzo D; Pansini F; Cambria R; Rondi E; Cattani F; Marvaso G; Zerini D; Vischioni B; Ciocca M; Russo S; Molinelli S; Golino F; Scroffi V; Rojas DP; Fodor C; Petralia G; Santoro L; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Tumori; 2016 Oct; 102(5):536-540. PubMed ID: 27514314
[TBL] [Abstract][Full Text] [Related]
6. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: a dose-escalation trial (DESTROY-4).
Deodato F; Ferro M; Bonome P; Pezzulla D; Romano C; Buwenge M; Cilla S; Morganti AG; Macchia G
Strahlenther Onkol; 2024 Mar; 200(3):239-249. PubMed ID: 38180492
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Integrated Radiotherapy Boost to the Dominant Intraprostatic Lesion: Final Results of a Phase I/II Trial.
Buwenge M; Alitto AR; Cilla S; Capocaccia I; Mazzeo E; Ippolito E; Mantini G; Siepe G; Cavallini L; Valentini V; Deodato F; Morganti AG; Macchia G
Anticancer Res; 2020 Nov; 40(11):6499-6503. PubMed ID: 33109589
[TBL] [Abstract][Full Text] [Related]
9. Twenty Fraction Prostate Radiotherapy with Intra-prostatic Boost: Results of a Pilot Study.
Onjukka E; Uzan J; Baker C; Howard L; Nahum A; Syndikus I
Clin Oncol (R Coll Radiol); 2017 Jan; 29(1):6-14. PubMed ID: 27692920
[TBL] [Abstract][Full Text] [Related]
10. MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial.
Alayed Y; D'Alimonte L; Helou J; Ravi A; Morton G; Chung HT; Haider M; McGuffin M; Zhang L; Loblaw A
Radiother Oncol; 2019 Dec; 141():144-148. PubMed ID: 31564554
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial.
Gomez-Iturriaga A; Casquero F; Urresola A; Ezquerro A; Lopez JI; Espinosa JM; Minguez P; Llarena R; Irasarri A; Bilbao P; Crook J
Radiother Oncol; 2016 Apr; 119(1):91-6. PubMed ID: 26900090
[TBL] [Abstract][Full Text] [Related]
12. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials.
Alayed Y; Davidson M; Liu S; Chu W; Tseng E; Cheung P; Vesprini D; Cheung H; Morton G; Musunuru HB; Ravi A; Korol R; Deabreu A; Ho L; Commisso K; Bhounr Z; D'Alimonte L; Mittmann N; Dragomir A; Zhang L; Loblaw A
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):136-142. PubMed ID: 31987962
[TBL] [Abstract][Full Text] [Related]
15. Effect of androgen deprivation therapy on intraprostatic tumour volume identified on
Chan J; Carver A; Brunt JN; Vinjamuri S; Syndikus I
Br J Radiol; 2017 Mar; 90(1071):20160818. PubMed ID: 27993093
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous integrated boost with stereotactic radiotherapy for dominant intraprostatic lesion of localized prostate cancer: a dosimetric planning study.
Kim YJ; Yoon KJ; Kim YS
Sci Rep; 2020 Sep; 10(1):14713. PubMed ID: 32895442
[TBL] [Abstract][Full Text] [Related]
17. MRI-guided localization of the dominant intraprostatic lesion and dose analysis of volumetric modulated arc therapy planning for prostate cancer.
Tamihardja J; Zenk M; Flentje M
Strahlenther Onkol; 2019 Feb; 195(2):145-152. PubMed ID: 30209535
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy Boost for the Dominant Intraprostatic Cancer Lesion-A Systematic Review and Meta-Analysis.
von Eyben FE; Kiljunen T; Kangasmaki A; Kairemo K; von Eyben R; Joensuu T
Clin Genitourin Cancer; 2016 Jun; 14(3):189-97. PubMed ID: 26768965
[TBL] [Abstract][Full Text] [Related]
19. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
